July 22, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Yamanouchi Terminates Marketing Agreement with Daiichi Suntory Pharma
 

Tokyo, Feb 18, 2005 (JCN) - Yamanouchi Pharmaceutical Co., Ltd. (TSE: 4503) has announced that is has agreed with Daiichi Suntory Pharma Co., Ltd. (TSE:) to terminate a marketing agreement between the two companies regarding the penem-type antibiotic Farom (faropenem sodium) on March 31, 2005.

After April 1, 2005, all marketing and detailing activities will be conducted by Maruho Co., Ltd.

In the fiscal year ended in March 2004, Yamanouchi posted sales of about 3.4 billion yen with these products.

By Dale Hug Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Yamanouchi Pharmaceutical Co., Ltd. News  
  Mega Pharmaceutical Astellas Pharma Kicks Off Operations  (Apr 1, 2005)
  Yamanouchi Pharmaceutical, Keio University Discover Target Molecule for Anti-obesity and Antidiabetic Drug  (Mar 25, 2005)
  Yamanouchi Terminates Marketing Agreement with Daiichi Suntory Pharma  (Feb 18, 2005)
  Yamanouchi Pharmaceutical to License Gelpart Coronary Embolism Material to Nippon Kayaku  (Feb 9, 2005)
  Yamanouchi Pharmaceutical to Transfer All Sanwell Shares to Asahi Breweries  (Feb 2, 2005)
  Lipitor, Atorvastatin Calcium Hydrate Greatly Inhibits Coronary Artery Plaque Progression: Yamanouchi Pharmaceutical, Pfizer Japan  (Jan 31, 2005)
  Yamanouchi Pharmaceutical, RIKEN Shed Light on Genetic Network of Biological Clock  (Jan 25, 2005)
  Yamanouchi to Market Vesicare for Treatment of Overactive Bladder in US  (Jan 21, 2005)
  Yamanouchi to Spin Off Formulation Plants  (Nov 10, 2004)
  Yamanouchi Obtains Approval for an Additional Dosage Form Using Its Proprietary OCAS Technology for Tamsulosin in the Treatment of Benign Prostatic Hyperplasia in the Netherlands  (Sept 22, 2004)



 Recent  Drugs & OTC News   
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)
Dainippon Screen Launches High-speed Three-dimensional Cell Culture Scanner (Aug 8, 2013)
Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria (Aug 1, 2013)

More Drugs & OTC news...

 Recent  Drugs & OTC News   
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)
Dainippon Screen Launches High-speed Three-dimensional Cell Culture Scanner (Aug 8, 2013)
Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria (Aug 1, 2013)

More Drugs & OTC news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)